Browse the evidence

Maintaining ideal cardiovascular health behaviors (nonsmoking, BMI ≤25, goal-level physical activity, healthy diet) and factors (untreated cholesterol ≤200, BP ≤120/80, fasting glucose ≤100) significantly reduces the risk of coronary heart disease, stroke, and diabetes, and improves longevity.

To maximize your heart health and longevity, focus on four key lifestyle areas: do not smoke, keep your BMI at or below 25, engage in at least 150 minutes of moderate physical activity per week, and eat a diet rich in fruits, vegetables, and whole grains. Additionally, ensure your untreated blood pressure is below 120/80, cholesterol is below 200, and fasting blood glucose is below 100. Achieving all these targets simultaneously offers the strongest protection against heart disease and stroke.

Trans-fatty acids (TFAs) increase the risk of coronary heart disease and sudden death more strongly than any other nutrient, primarily by raising LDL cholesterol and lowering HDL cholesterol.

Avoid trans-fatty acids completely. They are found in partially hydrogenated oils used in many processed foods. A 2% increase in energy from TFAs is linked to a 23% higher risk of heart disease. Check labels for 'partially hydrogenated oils' and avoid these products entirely.

First-line therapy for obesity involves lifestyle modification (energy-restricted diet and increased physical activity) aiming for 5-15% weight loss over 6 months, supported by pharmacotherapy or bariatric surgery for higher BMI or comorbidities.

Start with a 600 kcal daily deficit and 30-60 minutes of moderate exercise most days. Aim for 5-15% weight loss over 6 months. If BMI is >30 (or >27 with comorbidities), discuss pharmacotherapy (e.g., GLP-1 agonists) or bariatric surgery (if BMI >=40 or >=35 with comorbidities) with your doctor.

Multifactorial intervention targeting blood glucose, blood pressure, and lipids reduces cardiovascular mortality in type 2 diabetes more effectively than standard care focused only on glucose.

To prevent heart attacks, you must manage your blood pressure and cholesterol in addition to your blood sugar. A holistic approach is more effective than focusing on glucose alone.

Semaglutide (2.4 mg weekly) and Liraglutide (3.0 mg daily) are effective pharmacological adjuncts for obesity, producing significant weight loss (15% and 8-10% respectively) when combined with lifestyle interventions.

For patients with BMI ≥ 30 (or ≥ 25 with comorbidities) who do not achieve goals with lifestyle changes alone, consider GLP-1 analogues. Semaglutide 2.4mg weekly yields ~15% weight loss; Liraglutide 3mg daily yields ~8-10%. These are adjuncts to, not replacements for, behavioral therapy.

Intentional weight loss via GLP-1 receptor agonists (liraglutide, semaglutide) and SGLT2 inhibitors (empagliflozin) reduces cardiovascular events and mortality in type 2 diabetes patients, contradicting the 'obesity paradox' which suggests higher BMI is protective.

If you have Type 2 Diabetes, medications like GLP-1 agonists (e.g., liraglutide, semaglutide) or SGLT2 inhibitors (e.g., empagliflozin) are proven to help your heart and reduce weight. Do not rely on the 'obesity paradox' to justify carrying excess weight; these drugs actively reduce cardiovascular risk and mortality.

Increased consumption of ultra-processed foods is a major contributor to the global pandemics of obesity, type 2 diabetes, and related non-communicable diseases.

Prioritize fresh and minimally processed foods in your diet. Be aware that ultra-processed foods (UPFs) are a major driver of obesity and metabolic disease. UPFs are industrially formulated products high in sugars, unhealthy fats, and sodium, and low in fiber and protein. They are designed to be hyper-palatable and addictive. To improve health, reduce UPF consumption and replace them with whole or minimally processed alternatives. Policy changes are needed to make healthy foods more accessible and affordable.

Weekly subcutaneous tirzepatide (5-15 mg) produces significant, dose-dependent weight loss (-15% to -21%) and improves cardiometabolic markers in adults with overweight/obesity, including those with type 2 diabetes.

If you have obesity or overweight with related health issues, weekly tirzepatide injections, combined with diet and exercise, can lead to significant weight loss (15-21%) and improve heart and metabolic health. Start with a low dose to minimize side effects, and gradually increase it as tolerated.

Weekly subcutaneous semaglutide (2.4 mg) produces significant weight loss (-10%) and improves cardiometabolic markers in adults with overweight/obesity, including those with type 2 diabetes.

If you have obesity or overweight with related health issues, weekly semaglutide injections, combined with diet and exercise, can lead to significant weight loss (around 10%) and improve heart and metabolic health. Start with a low dose to minimize side effects, and gradually increase it as tolerated.

Weekly subcutaneous liraglutide (3.0 mg) produces significant weight loss (-5.24 kg) and improves cardiometabolic markers in adults with overweight/obesity, though it is less effective than semaglutide 2.4 mg.

If you have obesity or overweight with related health issues, daily liraglutide injections, combined with diet and exercise, can lead to moderate weight loss (around 5 kg) and improve heart and metabolic health. Start with a low dose to minimize side effects, and gradually increase it as tolerated. Note that it may be less effective than other options like semaglutide.

Novel anti-obesity medications (AOMs), specifically GLP-1 receptor agonists like semaglutide (2.4 mg weekly), achieve >10% body weight loss and lead to MASH resolution and fibrosis regression in patients with fibrotic MASH, offering a viable alternative to lifestyle changes alone.

Semaglutide 2.4 mg weekly is now FDA-approved for fibrotic MASH. It effectively resolves MASH and regresses fibrosis in many patients, offering a powerful tool when lifestyle changes are insufficient.

Aggressive LDL cholesterol lowering with high-dose statins (e.g., atorvastatin 80mg) significantly reduces major cardiovascular events and induces regression of coronary atherosclerosis in patients with type 2 diabetes, even when baseline LDL levels are within normal ranges.

If you have Type 2 Diabetes, your risk of heart disease is significantly higher than the general population. Current medical guidelines recommend statin therapy for most diabetic patients, regardless of whether your cholesterol numbers look 'normal' on a standard test. Aggressive treatment with high-dose statins (like atorvastatin 80mg) is proven to shrink existing plaque in your arteries and significantly reduce your risk of heart attack and stroke. This is a primary prevention strategy that should be discussed with your doctor, especially if you have other risk factors like high blood pressure or smoking history.

SGLT2 inhibitors and GLP-1 receptor agonists provide significant cardiovascular protection and should be prioritized in women with type 2 diabetes and high cardiovascular risk.

If you have diabetes and heart risk factors, ask your doctor about SGLT2 inhibitors (like Jardiance/Farxiga) or GLP-1 agonists (like Ozempic/Victoza). These drugs protect your heart and kidneys beyond just lowering blood sugar. Standard sugar-lowering pills may not be enough for heart protection.

The Five-Times-Sit-to-Stand Test (FTSST) serves as a valid, safe, and affordable diagnostic tool for assessing functional mobility, identifying sarcopenia risk, and predicting falls or cognitive impairment in adults aged 50+.

Use the Five-Times-Sit-to-Stand Test as a simple, free health check. Sit in a standard chair, fold your arms, and stand up and sit down five times as fast as you can. Time yourself. Compare your time to age- and sex-specific reference values (available in this study) to gauge your functional mobility. Slower times may indicate higher risks for falls, sarcopenia, or cognitive decline, prompting a conversation with a healthcare provider.

A semi-mechanistic exposure-response model using semaglutide 2.4 mg once weekly can accurately predict individual 1-year weight loss outcomes based on baseline demographics and early weight data (up to 28 weeks).

If you are starting semaglutide 2.4 mg, do not judge the treatment's effectiveness solely on your weight at week 0 or even week 4. The model shows that predictions become highly accurate (MAE ~3kg) only after incorporating weight data from weeks 8, 16, or 28. Use early weigh-ins to recalibrate expectations with your doctor rather than stopping treatment prematurely due to perceived lack of efficacy.

A 2-year low-carbohydrate diet produces greater weight loss and superior lipid profile improvements compared to a low-fat diet, while a Mediterranean diet offers superior glycemic control for individuals with type 2 diabetes.

If you struggle with weight loss on low-fat diets, try restricting carbohydrates. A low-carb approach (starting at 20g/day and moving to 120g/day) led to nearly double the weight loss of a standard low-fat diet in this 2-year study, along with better improvements in cholesterol ratios. If you have diabetes, a Mediterranean diet may offer better blood sugar control.

For individuals with type 2 diabetes, a Mediterranean diet provides superior glycemic control (fasting glucose and insulin sensitivity) compared to a low-fat diet.

If you have type 2 diabetes, a Mediterranean diet may help control your blood sugar better than a standard low-fat diet. This diet emphasizes vegetables, olive oil, and nuts, and limits red meat. In this study, it significantly improved insulin sensitivity and lowered fasting glucose in diabetic participants, whereas a low-fat diet did not.

Combining naltrexone SR (32 mg/day) and bupropion SR (360 mg/day) with intensive behavior modification produces significantly greater weight loss (9.3%) and cardiometabolic improvements compared to behavior modification alone (5.1%) in obese adults over 56 weeks.

If you have obesity, adding this specific combination of naltrexone and bupropion to a structured diet and exercise program can nearly double your average weight loss compared to diet and exercise alone. The medication is taken twice daily and requires a slow start to minimize nausea. It is most effective for those without diabetes or heart conditions.

High adherence to an intensive lifestyle intervention (ILI) comprising diet, physical activity, and behavioral counseling produces clinically significant weight loss (mean 8.6%) in adults with type 2 diabetes, with self-reported physical activity being the strongest correlate of success.

To lose significant weight with type 2 diabetes, commit to a structured lifestyle program. Aim for 175 minutes of brisk walking per week, gradually building up. Attend all counseling sessions, track your food, and use meal replacements (shakes/bars) for 1-2 meals daily. Physical activity is the strongest driver of success, so prioritize it alongside dietary changes.

Self-reported physical activity is the strongest correlate of weight loss in intensive lifestyle interventions for type 2 diabetes, accounting for 16.1% of the variance in weight loss outcomes.

Prioritize physical activity in your weight loss strategy. Aim for 175 minutes of brisk walking per week, gradually increasing your activity. This is the strongest predictor of successful weight loss in people with type 2 diabetes.

Structured commercial weight loss programs produce significantly greater weight loss and BMI reduction than self-help methods over a 2-year period, though both groups experience significant weight regain after the first year.

If you are trying to lose weight, joining a structured program like Weight Watchers is more effective than trying to do it alone with self-help resources. You will lose more weight and keep it off better for at least two years. However, expect some weight regain after the first year regardless of the method, so consistency is key.

Supervised aerobic exercise prescribed by verified energy expenditure (400-600 kcal/session, 5 days/week) without dietary restriction results in clinically significant weight loss (approx. 5%) in overweight/obese adults, with no significant difference between men and women.

To lose weight using exercise alone, you must burn a significant amount of energy (400-600 kcal) per session, 5 days a week, without changing your diet. It is not enough to just 'move more'; the volume must be high and verified. Men and women lose weight equally when the energy expenditure is matched. Expect to spend 40-60 minutes per session on cardio.

Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to lifestyle interventions, produces substantial and sustained weight loss (mean 14.9% at 68 weeks) and improves cardiometabolic risk factors in adults with overweight or obesity.

If you have obesity or overweight with related health issues, once-weekly semaglutide 2.4 mg combined with a modest calorie deficit and regular exercise can lead to significant, sustained weight loss (around 15% on average) and better heart health markers. Start with the lowest dose to minimize stomach upset, and expect side effects like nausea to fade over time.

Once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10-15 mg induce large, sustained reductions in body weight and waist circumference in adults with obesity without diabetes, significantly outperforming lifestyle interventions alone.

For individuals with obesity who have not achieved sustained weight loss through lifestyle changes alone, adding once-weekly semaglutide (2.4 mg) or tirzepatide (10-15 mg) to a lifestyle program can result in significant, clinically meaningful weight loss (12-19%) and waist circumference reduction. These treatments are generally well-tolerated, with side effects typically being mild gastrointestinal issues that diminish over time.